{"id":29130,"date":"2026-03-10T15:49:14","date_gmt":"2026-03-10T15:49:14","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/29130\/"},"modified":"2026-03-10T15:49:14","modified_gmt":"2026-03-10T15:49:14","slug":"h-c-wainwright-does-not-see-direct-read-from-roche-miss-to-olemas-opera-02","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/29130\/","title":{"rendered":"H.C. Wainwright does not see direct read from Roche miss to Olema\u2019s OPERA-02"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">H.C. Wainwright notes that Roche\u2019s (<a href=\"https:\/\/www.tipranks.com\/stocks\/rhhby?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:RHHBY;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;RHHBY&quot;}\" class=\"link \">RHHBY<\/a>) persevERA trial \u201cdisappointingly\u201d failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe the persevERA trial is \u201ca complete readthrough\u201d to Olema Oncology\u2019s (<a href=\"https:\/\/www.tipranks.com\/stocks\/olma?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:OLMA;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;OLMA&quot;}\" class=\"link \">OLMA<\/a>) OPERA-02 trial, which is evaluating palazestrant plus ribociclib. Differences in combo agents could favor OPERA-02, argues the analyst, who keeps a Buy rating on Olema shares.<\/p>\n<p class=\"yf-1fy9kyt\">Published first on <a href=\"https:\/\/thefly.com\/?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:TheFly;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;TheFly&quot;}\" class=\"link \">TheFly<\/a> \u2013 the ultimate source for real-time, market-moving breaking financial news. <a href=\"https:\/\/thefly.com\/?utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Try Now&gt;&gt;;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Try Now&amp;gt&quot;}\" class=\"link \">Try Now&gt;&gt;<\/a><\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.tipranks.com\/screener\/analysts-top-stocks\/?type=stockAnalysisLanding&amp;utm_source=finance.yahoo.com&amp;utm_medium=referral\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:See the top stocks recommended by analysts &gt;&gt;;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;See the top stocks recommended by analysts &amp;gt&quot;}\" class=\"link \">See the top stocks recommended by analysts &gt;&gt;<\/a><\/p>\n<p class=\"yf-1fy9kyt\">Read More on OLMA:<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.tipranks.com\/glossary\/d\/disclaimer-disclosure\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Disclaimer &amp; Disclosure;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Disclaimer &amp;amp&quot;}\" class=\"link \">Disclaimer &amp; Disclosure<\/a><a href=\"https:\/\/www.tipranks.com\/glossary\/c\/contact-editor\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Report an Issue;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Report an Issue&quot;}\" class=\"link \">Report an Issue<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"H.C. Wainwright notes that Roche\u2019s (RHHBY) persevERA trial \u201cdisappointingly\u201d failed, though the firm does not view the frontline&hellip;\n","protected":false},"author":2,"featured_media":29131,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[17548,151,134],"class_list":{"0":"post-29130","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-persevera","9":"tag-rhhby","10":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116205673755319951","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/29130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=29130"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/29130\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/29131"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=29130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=29130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=29130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}